La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Soligenix a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Soligenix..

Soligenix (NASDAQ:SNGX) Azioni, Catena delle Opzioni

Soligenix

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix Inc

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday.
The Dow traded down 0.15% to 44,393.57 while the NASDAQ rose 0.62% to 21,260.82. The S&amp;P 500 also rose, gaining, 0.27% to 6,380.37.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46756402/top-2-risk-off-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Risk Off Stocks That May Keep You Up At Night This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 2.5% on Thursday.
In trading on Thursday, health care stocks dipped by 0.8%.
Top Headline
Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported better-than-expected second-quarter financial results and issued third-quarter sales guidance above estimates on Wednesday.
Meta reported second-quarter revenue of $47.52 billion, beating analyst estimates of $44.58 billion, according to Benzinga Pro. The company reported second-quarter earnings of $7.14 per share, beating estimates of $5.79 per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares shot up 172% to $3.40 after the company reported better-than-expected second-quarter EPS and sales.</li>
<li>Shares of VerifyMe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) got a boost, surging 59% to $1.0909 after the company announced it entered into a 3-year UPS Digital Channel Program Agreement with the United Parcel Service.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) shares were also up, gaining 36% to $13.62 after the company reported better-than-expected quarterly adjusted EPS results. Additionally, Needham and HC Wainwright &amp; Co. raised their respective price targets on the stock.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares dropped 38% to $1.9499 after the company reported second-quarter financial results and cut its FY25 sales guidance below estimates. Also, Piper Sandler downgraded the stock from Overweight to Neutral and cut its price target from $9 to $2.5, while D. Boral Capital cut its price target from $17 to $16.</li>
<li>Shares of Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) were down 33% to $136.89 after the company missed second-quarter earnings estimates and issued soft third-quarter guidance.</li>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) was down, falling 28% to $1.4905 as the company reported 6-week interim biomarker results from Phase 2a idiopathic pulmonary fibrosis study.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $69.25 while gold traded down 0.2% at $3,346.70.
Silver traded down 3.2% to $36.54 on Thursday, while copper fell 22% to $4.3600.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.57%, while Spain's IBEX 35 Index gained 0.33%. London's FTSE 100 rose 0.01%, Germany's DAX 40 declined 0.70% and France's CAC 40 fell 0.71% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 1.02%, Hong Kong's Hang Seng falling 1.60%, China's Shanghai Composite dipping 1.18% and India's BSE Sensex falling 0.36%.
Economics
<ul class="wp-block-list">
<li>The core PCE price index rose 0.3% from the previous month in June.</li>
<li>Personal spending rose 0.3% month-over-month in June, while personal income rose by 0.3% month-over-month to $25.794 trillion.</li>
<li>U.S. initial jobless claims rose by 1,000 from the previous week to 218,000 in the fourth week of July, compared to market estimates of 224,000.</li>
<li>U.S. employment costs rose by 0.9% in the second quarter.</li>
<li>U.S.-based employers announced job cuts of 62,075 in July.</li>
<li>U.S. natural-gas stocks rose 48 billion cubic feet in the week ending July 25.</li>
<li>The Chicago Business Barometer climbed to 47.1 in July versus 40.4 in June.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46755797/amazon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2">Amazon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo via Shutterstock

Earnings

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ALGN

APLD

ALPS ETF Trusthen & Steers Global Realty Majors ETF

LUNG

SNGX

VRME

Crude Oil Falls 1%; Meta Earnings Top Views

<h3>Gainers</h3>
<ul>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares rose 192.0% to $3.65 during Thursday's regular session. The market value of their outstanding shares is at $4.0 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) stock rose 22.13% to $2.89. The market value of their outstanding shares is at $72.6 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares increased by 21.73% to $3.91. The market value of their outstanding shares is at $1.6 million. </li>
<li>SNDL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares increased by 21.18% to $1.75. The company's market cap stands at $370.5 million. As per the press release, Q2 earnings came out today. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares moved upwards by 18.6% to $0.54. The market value of their outstanding shares is at $23.3 million. </li>
<li>Jyong Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MENS#NASDAQ">MENS</a>) shares increased by 18.56% to $21.3. The company's market cap stands at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 39.7% to $1.9 during Thursday's regular session. The company's market cap stands at $125.3 million. The company's, Q2 earnings came out yesterday. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock fell 37.35% to $1.28. The market value of their outstanding shares is at $5.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares decreased by 36.5% to $0.31. The company's market cap stands at $3.4 million. </li>
<li>Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares declined by 35.12% to $132.09. The company's market cap stands at $14.7 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) shares decreased by 19.12% to $22.69. The company's market cap stands at $14.3 billion. As per the press release, Q2 earnings came out today. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock declined by 15.0% to $0.67. The market value of their outstanding shares is at $1.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

MENS

NSPR

ONCO

OTRK

PSTV

SLRX

SNDL

12 Health Care Stocks Moving In Thursday's Intraday Session

<a href="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07312025_SNGX_Bautz.pdf" title="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07312025_SNGX_Bautz.pdf">https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07312025_SNGX_Bautz.pdf</a>

Analyst Ratings

Watching Soligenix; Zacks Small-Cap Research Gives Stock $35 Price Valuation

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 1% on Thursday.
Following the market opening Thursday, the Dow traded up 0.24% to 44,566.33 while the NASDAQ rose 1.26% to 21,395.66. The S&amp;P 500 also rose, gaining, 0.76% to 6,411.57.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46756402/top-2-risk-off-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Risk Off Stocks That May Keep You Up At Night This Month</a>
Leading and Lagging Sectors Communication services shares jumped by 2.9% on Thursday.
In trading on Thursday, health care stocks dipped by 0.7%.
Top Headline
Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) reported better-than-expected fourth-quarter financial results and issued strong forecast for the current quarter on Wednesday.
Microsoft reported fourth-quarter revenue of $76.44 billion, up 17% year-over-year. The revenue total beat a Street consensus estimate of $73.80 billion according to data from Benzinga Pro. The company reported fourth-quarter earnings per share of $3.65, beating a Street consensus estimate of $3.37.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares shot up 73% to $2.1793 after the company reported better-than-expected second-quarter EPS and sales.</li>
<li>Shares of VerifyMe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) got a boost, surging 64% to $1.1250 after the company announced it entered into a 3-year UPS Digital Channel Program Agreement with the United Parcel Service.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares were also up, gaining 55% to $8.32 after the company announced it, along with PsyLabs, achieved a breakthrough in GMP-aligned high-purity ibogaine production.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares dropped 37% to $1.9750 after the company reported second-quarter financial results and cut its FY25 sales guidance below estimates. Also, Piper Sandler downgraded the stock from Overweight to Neutral and cut its price target from $9 to $2.5, while D. Boral Capital cut its price target from $17 to $16.</li>
<li>Shares of Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) were down 31% to $140.66 after the company missed second-quarter earnings estimates and issued soft third-quarter guidance.</li>
<li>GRI Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) was down, falling 31% to $1.43 as the company reported 6-week interim biomarker results from Phase 2a idiopathic pulmonary fibrosis study.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $69.46 while gold traded up 0.1% at $3,354.30.
Silver traded down 2.8% to $36.675 on Thursday, while copper fell 21.4% to $4.3860.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.4%, while Spain's IBEX 35 Index gained 0.2%. London's FTSE 100 rose 0.2%, Germany's DAX 40 declined 0.5% and France's CAC 40 fell 0.5% during the session.
Asia Pacific Markets
Asian markets closed mostly lower on Thursday, with Japan's Nikkei 225 gaining 1.02%, Hong Kong's Hang Seng falling 1.60%, China's Shanghai Composite dipping 1.18% and India's BSE Sensex falling 0.36%.
Economics
<ul class="wp-block-list">
<li>The core PCE price index rose 0.3% from the previous month in June.</li>
<li>Personal spending rose 0.3% month-over-month in June, while personal income rose by 0.3% month-over-month to $25.794 trillion.</li>
<li>U.S. initial jobless claims rose by 1,000 from the previous week to 218,000 in the fourth week of July, compared to market estimates of 224,000.</li>
<li>U.S. employment costs rose by 0.9% in the second quarter.</li>
<li>U.S.-based employers announced job cuts of 62,075 in July.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46755797/amazon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call-2">Amazon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>
Photo via Shutterstock

MSFT

Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings

Soligenix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares surged on Thursday as the company announced positive results from its Phase 2a proof-of-concept study of SGX945 (dusquetide) in Behçet&#8217;s disease, a rare and chronic inflammatory condition.
The session volume reached 28.71 million shares, significantly above the stock&#8217;s average daily volume of approximately 905,000, according to <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
The company reported that SGX945 achieved the trial&#8217;s primary goal of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46752465/biological-efficacy-demonstrated-in-a-phase-2-clinical-trial-of-sgx945-for-the-treatment-of-beh-et" rel="noreferrer noopener">demonstrating biological efficacy</a> in treating oral ulcers, a hallmark symptom of Behçet&#8217;s disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42970323/exclusive-soligenixs-cancer-candidate-shows-encouraging-action-with-extended-treatment-at-one-year" rel="noreferrer noopener">EXCLUSIVE: Soligenix&#8217;s Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year</a>
This disorder, while rare, presents serious quality-of-life challenges for patients due to <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">recurrent mouth and genital sores</a>, eye inflammation, and painful skin lesions.
The Phase 2a study was an open-label study designed to be highly comparable to the published Phase 3 study of Amgen Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) apremilast (Otezla) used to support marketing approval for oral ulcers in Behçet&#8217;s disease. SGX945 outcomes were compared to the apremilast and placebo arms in this Phase 3 study.
Over 4 weeks of treatment, the area under the curve (AUC; a composite measurement of both peak number of oral ulcers and the time to resolution of the oral ulcers), average number of oral ulcers, and improvements in oral pain for SGX945 were similar to outcomes obtained in the apremilast study.
Outcomes in weeks 5 through 8 continued to show similar outcomes to the apremilast study, even though apremilast treatment was continued through this period whereas SGX945 treatment was stopped at Week 4, per study design. The primary endpoint in the Phase 3 apremilast study was the AUC of the mean number of ulcers versus time.
Using this same endpoint after 4 weeks of treatment, the SGX945-treated group had a 40% improvement relative to the placebo group from the Phase 3 apremilast study, whereas apremilast had a 37% improvement relative to the placebo.
This improvement was sustained throughout the 4-week follow-up after treatment with SGX945, with 32% improvement evaluated at Week 8 despite treatment having stopped at Week 4.
In contrast, apremilast, which was continuously administered through Week 12, had a 41% improvement at Week 8. The improvements in oral pain mimicked the results in the&nbsp;AUC measurement.
Seven of 8 patients reported perceived benefit with SGX945 treatment, with common outcomes including reduced duration of oral ulcers, reduced number of oral ulcers, and reduced oral pain. One patient began the study with a punctuated skin ulcer, which also resolved during the 4-week treatment with SGX945.
SGX945 was well-tolerated with no treatment-related adverse events. Common adverse events for apremilast included diarrhea (41% of patients), nausea (19% of patients), and headache (14% of patients), none of which were observed with SGX945.
Price Action: SNGX stock is trading higher by 46.4% to $1.830 premarket at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46749278/chuck-schumer-says-scott-bessent-slipped-and-told-the-truth-about-trumps-social-security-privatization-plan" target="_blank" rel="noreferrer noopener">Chuck Schumer Says Scott Bessent &#8216;Slipped&#8217; And &#8216;Told The Truth&#8217; About Trump&#8217;s Social Security Privatization Plan</a></li>
</ul>
Image by PeopleImages.com &#8211; Yuri A via Shutterstock

Biotech

Health Care

General

AMGN

Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial

<h3>Gainers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 62.6% to $8.78 during Thursday's pre-market session. The company's market cap stands at $3.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares rose 42.3% to $2.96. The company's market cap stands at $4.9 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 25.23% to $4.02. The company's market cap stands at $1.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares rose 21.59% to $1.52. The market value of their outstanding shares is at $4.0 million. </li>
<li>Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) shares rose 19.21% to $15.5. The company's market cap stands at $2.4 billion. The company's, Q2 earnings came out yesterday. </li>
<li>TransMedics Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock moved upwards by 16.75% to $125.75. The market value of their outstanding shares is at $3.6 billion. The company's, Q2 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Align Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>) shares decreased by 31.6% to $139.21 during Thursday's pre-market session. The company's market cap stands at $14.7 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 19.69% to $2.53. The company's market cap stands at $125.3 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares decreased by 17.89% to $6.2. The market value of their outstanding shares is at $157.7 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock fell 12.76% to $3.42. The market value of their outstanding shares is at $527.2 million. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock decreased by 11.5% to $1.0. The company's market cap stands at $34.0 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares fell 10.91% to $0.98. The company's market cap stands at $15.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALHC

DYAI

ENSC

NVCT

PRME

PTHL

TMDX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

WIIM

Soligenix shares are trading higher after the company announced positive Phase 2a proof-of-concept results for SGX945 in Behçet's Disease, demonstrating biological efficacy.

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,&nbsp;announced today that it has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4478637-1&amp;h=3362255736&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx945-for-aphthous-ulcers-of-behcets-disease%2F&amp;a=treatment+of+Beh%C3%A7et%27s+Disease">treatment of Behçet's Disease</a> and achieved the study objective of demonstrating biological efficacy.

Soligenix Completes Phase 2a Proof Of Concept Study Evaluating SGX945 In Behçet's Disease, Showing Biological Efficacy

Alliance Global Partners analyst James Molloy maintains Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) with a Buy and lowers the price target from $10 to $6.

Price Target

Alliance Global Partners Maintains Buy on Soligenix, Lowers Price Target to $6

<a href="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf" title="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf">https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf</a>

Looking ahead to 2026, Soligenix is positioning itself for a pivotal year marked by key clinical milestones and potential catalysts across its rare disease pipeline. Most notably, the company anticipates releasing top-line results from its confirmatory Phase 3 FLASH2 trial of HyBryte&#x2122; for early-stage cutaneous T-cell lymphoma in the second half of the year. With enrollment on track and prior data showing promising efficacy and safety, the outcome of FLASH2 could be transformational for HyBryte's regulatory and commercial trajectory. Soligenix is also actively exploring strategic partnerships and M&amp;A opportunities to maximize value creation, while targeting global marketing authorizations. Backed by a diversified pipeline, solid early clinical data, and an expanding manufacturing footprint, the company sees 2026 as a potential inflection point in its mission to deliver impactful therapies for underserved patient populations.
&nbsp;
&nbsp;

Soligenix Issues Corporate Update Highlighting FLASH2 Phase 3 Progress, Psoriasis and Behçet's Trial Milestones, and Strategic Outlook Through 2026

<h3>Gainers</h3>
<ul>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock rose 24.9% to $3.11 during Wednesday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares rose 12.58% to $24.69. The company's market cap stands at $143.8 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 11.72% to $1.62. The company's market cap stands at $6.6 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares increased by 11.57% to $1.35. The market value of their outstanding shares is at $3.8 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares rose 11.53% to $0.79. The market value of their outstanding shares is at $38.4 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 11.11% to $1.1. The company's market cap stands at $4.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 30.2% to $39.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares declined by 27.32% to $1.49. The company's market cap stands at $8.9 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) stock decreased by 12.31% to $3.35. The market value of their outstanding shares is at $69.8 million. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock declined by 10.86% to $0.41. The market value of their outstanding shares is at $104.9 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares fell 10.71% to $0.73. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares decreased by 9.93% to $1.27. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNTA

MBIO

MODD

NIVF

REVB

SBFM

SCNI

SONN

VXRT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares increased by 32.3% to $19.77 during Tuesday's regular session. The market value of their outstanding shares is at $213.2 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock increased by 32.16% to $0.4. The company's market cap stands at $4.7 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 27.66% to $1.16. The market value of their outstanding shares is at $2.4 million. </li>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) shares increased by 25.47% to $3.96. The company's market cap stands at $18.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock increased by 18.32% to $1.55. The market value of their outstanding shares is at $4.2 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares moved upwards by 18.22% to $1.13. The company's market cap stands at $4.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock fell 57.3% to $1.63 during Tuesday's regular session. The company's market cap stands at $2.7 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 46.0% to $0.47. The market value of their outstanding shares is at $13.7 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) stock fell 31.23% to $4.89. The market value of their outstanding shares is at $12.8 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) stock decreased by 28.33% to $9.51. The company's market cap stands at $7.2 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 14.64% to $6.01. The market value of their outstanding shares is at $44.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) shares fell 14.16% to $8.28. The company's market cap stands at $488.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ARTL

CLRB

EHAB

GOVX

LIXT

NGNE

OGEN

VVOS

XCUR

12 Health Care Stocks Moving In Tuesday's Intraday Session

Soligenix shares are trading higher after the company announced it successfully completed the manufacturing process of synthetic hypericin to Sterling Pharma Solutions.

<h3>Gainers</h3>
<ul>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock rose 64.9% to $2.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.2 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares rose 48.69% to $5.68. The company's market cap stands at $2.7 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares rose 21.52% to $0.64. The market value of their outstanding shares is at $49.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares increased by 21.13% to $1.26. The market value of their outstanding shares is at $4.4 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) stock moved upwards by 12.85% to $12.29. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) shares rose 10.61% to $0.5. The market value of their outstanding shares is at $103.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pulmatrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PULM#NASDAQ">PULM</a>) shares decreased by 23.9% to $5.25 during Tuesday's pre-market session. The market value of their outstanding shares is at $25.2 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock decreased by 17.88% to $4.18. The company's market cap stands at $10.2 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) stock declined by 16.92% to $2.53. The market value of their outstanding shares is at $55.6 million. </li>
<li>Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) stock declined by 16.73% to $11.05. The market value of their outstanding shares is at $7.2 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock declined by 14.21% to $6.04. The market value of their outstanding shares is at $44.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock fell 11.64% to $0.77. The market value of their outstanding shares is at $13.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MESO

PULM

SNES

VRCA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Active Ingredient Manufacturing Transfer to the U.S. Complete&nbsp;
PRINCETON, N.J., July 1, 2025 /PRNewswire/ --&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

Soligenix Transfers Manufacturing Process For Synthetic Hypericin Active Ingredient Under Partnership Agreement With Sterling Pharma Solutions

&nbsp;Soligenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has successfully completed the transfer of the manufacturing process for its synthetic hypericin active ingredient under its partnership agreement with Sterling Pharma Solutions (Sterling). The transfer from Europe to the United States (U.S.) included the optimization and implementation of a commercially viable, scalable production process for this important active ingredient, which is used in the topical drug product formulations <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=193312477&amp;u=https%3A%2F%2Fwww.hybryte.com%2F&amp;a=HyBryte%E2%84%A2">HyBryte&#x2122;</a> and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4459945-1&amp;h=1271944488&amp;u=https%3A%2F%2Fwww.soligenix.com%2Fpipeline-programs%2Fsgx302-for-mild-to-moderate-psoriasis%2F&amp;a=SGX302">SGX302</a> being developed for the treatment of cutaneous T-cell lymphoma (CTCL) and psoriasis, respectively. Synthetic hypericin is a potent photosensitizer that is topically applied to skin lesions. Soligenix and Sterling have enabled cGMP (current good manufacturing practice) manufacturing for clinical trials with the intent of establishing a long-term commercial manufacturing collaboration.

Soligenix Announces That is Successfully Manufactured Synthetic Hypericin At Sterling Pharma Solutions

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock increased by 128.3% to $21.78 during Tuesday's regular session. The market value of their outstanding shares is at $118.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 106.64% to $0.7. The company's market cap stands at $10.3 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares rose 71.71% to $9.41. The market value of their outstanding shares is at $15.7 million. </li>
<li>Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) stock increased by 32.85% to $16.74. The market value of their outstanding shares is at $260.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares increased by 29.29% to $0.71. The company's market cap stands at $10.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares rose 27.51% to $25.5. The company's market cap stands at $520.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock declined by 37.9% to $1.0 during Tuesday's regular session. The market value of their outstanding shares is at $19.4 million. </li>
<li>Ernexa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) stock decreased by 19.17% to $1.94. The company's market cap stands at $17.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares fell 18.49% to $1.34. The market value of their outstanding shares is at $5.3 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares fell 12.09% to $3.94. The market value of their outstanding shares is at $85.2 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock fell 11.72% to $0.44. The company's market cap stands at $8.0 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares fell 11.6% to $0.23. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMRN

ERNA

EYEN

INDP

LIMN

NKTR

NTHI

ONMD

TRIB

<h3>Gainers</h3>
<ul>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) stock rose 172.2% to $25.97 during Tuesday's pre-market session. The company's market cap stands at $118.3 million. </li>
<li>InMed Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) stock moved upwards by 88.53% to $4.62. The company's market cap stands at $2.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock increased by 53.21% to $0.84. The market value of their outstanding shares is at $10.5 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares increased by 47.43% to $1.05. The market value of their outstanding shares is at $11.5 million. </li>
<li>Crescent Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) stock rose 37.18% to $20.99. The market value of their outstanding shares is at $298.3 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) shares increased by 24.68% to $0.23. The company's market cap stands at $1.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares decreased by 30.4% to $1.12 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares fell 19.35% to $0.4. The market value of their outstanding shares is at $8.0 million. </li>
<li>ViewBix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIX#NASDAQ">VBIX</a>) shares declined by 14.48% to $3.31. The company's market cap stands at $25.6 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares declined by 13.34% to $1.43. The market value of their outstanding shares is at $5.3 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) stock fell 11.39% to $1.09. The company's market cap stands at $19.0 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock declined by 11.05% to $0.21. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

CBIO

DHAI

IBIO

VBIX

SNGX stock has given up its prior loss. Soligenix shares were trading lower after the company reported worse-than-expected Q1 EPS results.

Press Releases

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

IBN Initiates Coverage of Soligenix Inc.

Small Cap

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Loop Industries (Nasdaq: LOOP) Unveils Game-Changing Twist™ Polyester Made Entirely from Textile Waste – More Stocks Inside

LOOP

SNYR

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Ainos

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Aprea Therapeutics

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

enGene Holdings

HCW Biologics

HOOKIPA Pharma

iBio

Immuron Limited - American Depositary Shares

Immuron

MetaVia

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Turnstone Biologics

Alliance Global Partners

Screenshot 2025-05-02 at 5.43.08 PM

Soligenix Issues Interim Results For CTCL Treatment Trial – 75% Response At 18 Weeks, 3 Patients Achieve Complete Response

Screenshot 2025-04-23 at 10.53.10 PM

Soligenix&#39;s HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding

Screenshot 2025-02-24 at 11.30.54 PM

Interview

Soligenix Aims To Push The Boundaries In Treating Rare Diseases

Screenshot 2025-02-20 at 6.32.00 PM

Soligenix&#39;s Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026

Screenshot 2025-02-18 at 6.39.51 PM

Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behçet&#39;s Disease

Screenshot 2025-01-16 at 7.00.06 PM

Soligenix Targets Psoriasis With New Therapy

Screenshot 2024-12-16 at 6.43.37 PM

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL

Screenshot 2024-11-26 at 8.32.36 PM

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs

Comments

Soligenix

Soligenix (SNGX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO